CLAG Regimen Composed of Continuous Intravenous Infusion of Cladribine in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2021.02.005
- Author:
Rui-Hua MI
1
;
Lin CHEN
1
;
Hai-Ping YANG
2
;
Xian-Jing WANG
3
;
Shu-Li GUO
4
;
Lin SHI
5
;
Qing-Song YIN
1
;
Xu-Dong WEI
6
Author Information
1. Henan Cancer Hospital/The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, Henna Province, China.
2. Department of Hematology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471000, Henan Province, China.
3. Department of Hematology, The Third People's Hospital of Zhengzhou, Zhengzhou 450000, Henan Province, China.
4. Department of Hematology, Luoyang Central Hospital, Luoyang 471000, Henan Province, China.
5. Department of Hematology, Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou 450000, Henan Province, China.
6. Henan Cancer Hospital/The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, Henna Province, China,E-mail: weixudong63@126.com.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Antineoplastic Combined Chemotherapy Protocols;
Cladribine/therapeutic use*;
Cytarabine/therapeutic use*;
Female;
Granulocyte Colony-Stimulating Factor/therapeutic use*;
Humans;
Infusions, Intravenous;
Leukemia, Myeloid, Acute/drug therapy*;
Male;
Middle Aged;
Retrospective Studies;
Treatment Outcome;
Young Adult
- From:
Journal of Experimental Hematology
2021;29(2):333-338
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the efficacy and safety of continuous intravenous infusion of 2-Chlorodeoxyadenosine (2-CdA) combined with high-dose cytarabine (Ara-C) and granulocyte colony-stimulating factor (G-CSF) (CLAG regiem) in the treatment of relapsed/refractory acute myeloid leukemia (AML).
METHODS:Fifteen patients with refractory/relapsed AML hospitalized in 5 medical units such as Department of Hematology, the Affiliated Tumor Hospital of Zhengzhou University and received one course of CLAG regimen from June 2014 to August 2019 were analyzed retrospectively (specifically: cladribine 5 mg/M
RESULTS:Among the 15 patients with refractory/relapsed AML, 9 males and 6 females, the median age was 35 (13-63) years old. FAB classification: 1 case of M
CONCLUSION:The CLAG regimen consisting of continuous intravenous infusion of cladribine shows high CR in the treatment of AML patients, but the duration of CR is short, myelosuppression is sever, so that infection control is the key. Allogeneic hematopoietic stem cells transplantation should be performed as soon as possible after CR.
